Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 4 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Neoplasms 5Vipoma 4Carcinoma, Islet Cell 4Somatostatinoma 3Neuroendocrine Tumors 3Intestinal Obstruction 3Insulinoma 3Glucagonoma 3Gastrinoma 3Carcinoma, Hepatocellular 3Thymoma 2Stomach Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Meningioma 2Diarrhea 2Carcinoma 2Carcinoid Tumor 2Adenoma, Islet Cell 2Weight Loss 1Waldenstrom Macroglobulinemia 1Vomiting 1Recurrence 1Rectal Neoplasms 1Primary Inoperable Thymoma 1Pleural Effusion 1Pheochromocytoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Octreotide 2telotristat ethyl 1isatuximab 1ceterizine hydrochloride 1capivasertib 1cabazitaxel 1XRP6258 1Prednisone 1Loperamide 1Leucovorin 1Lapatinib 1Irinotecan 1Injections 1Granulocyte Colony-Stimulating Factor 1Fulvestrant 1Fluorouracil 1Filgrastim 1Drugs, Investigational 1Cyclophosphamide 1Colesevelam Hydrochloride 1Cell- and Tissue-Based Therapy 1Capecitabine 1Calcium Aluminosilicate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Diarrhea × Octreotide × Clear all
NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Novartis

Phase 2 Terminated
62 enrolled 25 charts
Breast

Breast Neoplasms, Diarrhea, Neoplasms

NCT01469338 2014-11-24

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

University of Southern California

Phase 2 Terminated
9 enrolled
Genitourinary

Diarrhea, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡